Clinical response and mortality in tigecycline complicated intra-abdominal infection and complicated skin and soft-tissue infection trials

International Journal of Antimicrobial Agents

Volumn 46, Issue 3, 2015, Pages 346-350

  Bassetti, Matteo ^a   McGovern, Paul C ^b   Wenisch, Christoph ^c   Meyer, R Daniel ^b   Yan, Jean Li ^b   Wible, Michele ^b   Rottinghaus, Scott T ^b   Quintana, Alvaro ^b  

^a SANTA MARIA DELLA MISERICORDIA UNIVERSITY HOSPITAL   (Italy)

^b PFIZER INC   (United States)

^c KAISER FRANZ JOSEF HOSPITAL   (Austria)

Author keywords

All cause; Glycylcycline; Mortality; Risk factor; Tigecycline

Indexed keywords

TIGECYCLINE; ANTIINFECTIVE AGENT; MINOCYCLINE;

ABDOMINAL INFECTION; ARTICLE; CAUSE OF DEATH; CONTROLLED STUDY; DESCRIPTIVE RESEARCH; DISEASE SEVERITY; DRUG RESPONSE; DRUG SAFETY; DRUG TREATMENT FAILURE; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MORTALITY; PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); PNEUMONIA; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; RISK FACTOR; SKIN INFECTION; SOFT TISSUE INFECTION; TREATMENT OUTCOME; VOMITING; ADULT; AGED; ANALOGS AND DERIVATIVES; COMPLICATION; FEMALE; INTRAABDOMINAL INFECTIONS; MALE; MIDDLE AGED; PNEUMONIA, BACTERIAL; SKIN DISEASES, BACTERIAL; SOFT TISSUE INFECTIONS; SURVIVAL ANALYSIS; TREATMENT FAILURE;

ADULT; AGED; ANTI-BACTERIAL AGENTS; CLINICAL TRIALS, PHASE III AS TOPIC; CLINICAL TRIALS, PHASE IV AS TOPIC; FEMALE; HUMANS; INTRAABDOMINAL INFECTIONS; MALE; MIDDLE AGED; MINOCYCLINE; PNEUMONIA, BACTERIAL; SKIN DISEASES, BACTERIAL; SOFT TISSUE INFECTIONS; SURVIVAL ANALYSIS; TREATMENT FAILURE;

EID: 84940452876     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2015.05.012     Document Type: Article

References (15)

1. Wyeth Pharmaceuticals Inc. Tygacil [prescribing information] 2013 Wyeth Pharmaceuticals Inc. Philadelphia, PA http://labeling.pfizer.com/showlabeling.aspx?id=491 [accessed 16.09.14]
2. P.C. McGovern, M. Wible, A. El-Tahtawy, P. Biswas, and R.D. Meyer All-cause mortality imbalance in the tigecycline phase 3 and 4 clinical trials Int J Antimicrob Agents 41 2013 463 467
3. A.T. Freire, V. Melnyk, M.J. Kim, O. Datsenko, O. Dzyublik, F. Glumcher, and et al. Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia Diagn Microbiol Infect Dis 68 2010 140 151
4. J. Ramirez, N. Dartois, H. Gandjini, J.L. Yan, J. Korth-Bradley, and P.C. McGovern Randomized phase 2 trial to evaluate the clinical efficacy of two high-dosage tigecycline regimens versus imipenem-cilastatin for treatment of hospital-acquired pneumonia Antimicrob Agents Chemother 57 2013 1756 1762
5. P. Prasad, J. Sun, R.L. Danner, and C. Natanson Excess deaths associated with tigecycline after approval based on noninferiority trials Clin Infect Dis 54 2012 1699 1709
6. D. Yahav, A. Lador, M. Paul, and L. Leibovici Efficacy and safety of tigecycline: a systematic review and meta-analysis J Antimicrob Chemother 66 2011 1963 1971
7. J. Breedt, J. Teras, J. Gardovskis, F.J. Maritz, T. Vaasna, D.P. Ross, et al. Tigecycline 305 cSSSI Study Group Safety and efficacy of tigecycline in treatment of skin and skin structure infections: results of a double-blind phase 3 comparison study with vancomycin-aztreonam Antimicrob Agents Chemother 49 2005 4658 4666
8. P. Fomin, M. Beuran, A. Gradauskas, G. Barauskas, A. Datsenko, N. Dartois, et al. Three Hundred Six Study Group Tigecycline is efficacious in the treatment of complicated intra-abdominal infections Int J Surg 3 2005 35 47
9. P. Matthews, M. Alpert, G. Rahav, D. Rill, E. Zito, D. Gardiner, et al. Tigecycline 900 cSSSI Study Group A randomized trial of tigecycline versus ampicillin-sulbactam or amoxicillin-clavulanate for the treatment of complicated skin and skin structure infections BMC Infect Dis 12 2012 297
10. M.E. Oliva, A. Rekha, A. Yellin, J. Pasternak, M. Campos, G.M. Rose, et al. 301 Study Group A multicenter trial of the efficacy and safety of tigecycline versus imipenem/cilastatin in patients with complicated intra-abdominal infections [Study ID Numbers: 3074A1-301-WW; ClinicalTrials.gov Identifier: NCT00081744] BMC Infect Dis 5 2005 88
11. N. Qvist, B. Warren, H. Leister-Tebbe, E.T. Zito, R. Pedersen, P.C. McGovern, and et al. Efficacy of tigecycline versus ceftriaxone plus metronidazole for the treatment of complicated intra-abdominal infections: results from a randomized, controlled trial Surg Infect (Larchmt) 13 2012 102 109
12. S. Sacchidanand, R.L. Penn, J.M. Embil, M.E. Campos, D. Curcio, E. Ellis-Grosse, and et al. Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: results from a phase 3, randomized, double-blind trial Int J Infect Dis 9 2005 251 261
13. S. Towfigh, J. Pasternak, A. Poirier, H. Leister, and T. Babinchak A multicentre, open-label, randomized comparative study of tigecycline versus ceftriaxone sodium plus metronidazole for the treatment of hospitalized subjects with complicated intra-abdominal infections Clin Microbiol Infect 16 2010 1274 1281
14. Z. Chen, J. Wu, Y. Zhang, J. Wei, X. Leng, J. Bi, and et al. Efficacy and safety of tigecycline monotherapy vs. imipenem/cilastatin in Chinese patients with complicated intra-abdominal infections: a randomized controlled trial BMC Infect Dis 10 2010 217
15. P.C. Austin, and J.V. Tu Bootstrap methods for developing predictive models Am Stat 58 2004 131 137